HIỆU QUẢ VÀ TÁC DỤNG PHỤ CỦA PHÁC ĐỒ BỐN THUỐC CHỨA BISMUTH TRONG DIỆT TRỪ HELICOBACTER PYLORI LẦN ĐẦU VÀ LẦN HAI TẠI VIỆT NAM

Abstract

Aim: To assess the safety and efficacy of bismuth quadruple therapy as first-line and second-line treatment in patients with Helicobacter pylori in Vietnam. Subject and methods: This was a retrospective, prospective and descriptive  study of the results of H. pylori eradication with bismthuth quadruple therapy in Vietnam. The experience consisted of 10 studies with 1.303 patients. In 1303 patients were treated with bismuth quadruple therapy, 1089 patients received the first-line treatment and 214  patients received the second-line treatment. The eradication rate of H. pylori is described both as per protocol (PP) analyses and intention-to-treat (ITT) analyses. Results:  The rate of first eradication of H. pylori with bismuth quadruple regimen according to intent to treat (ITT) and study design (PP) was 86.6% and 93.2%, respectively. The rate of second eradication of H. pylori with bismuth quadruple regimen according to intent to treat (ITT) and study design (PP) was 87.3% and 89.9%, respectively. Side effects when using bismuth quadruple regimen after the first-line  and second-line therapy were 66.9% and 58.5%, respectively. However, most side effects were mild. Conclusion: Bismuth quadruple regimen is highly effective and safe for the first and second eradication of H. pylori.